Merck reports Phase II data for c-MET inhibitor tepotinib in lung adenocarcinoma

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, Merck KGaA (Xetra:MRK) reported data from 3 evaluable patients with advanced lung adenocarcinoma in a Phase II trial showing that once-daily 500 mg oral tepotinib (MSC2156119J) led to 2 unconfirmed partial responses and 1 case of stable disease. Tepotinib was well tolerated.

The open-label, international trial is enrolling about 60 lung adenocarcinoma patients who previously failed 1-2 prior therapies, including a platinum-doublet-containing regimen, and whose tumors harbor a skipping mutation in exon 14 of c-MET receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene)...